Saturday, 21 May, 2022
TopicBharat Biotech

Topic: Bharat Biotech

WHO move to suspend Covaxin’s UN supply won’t affect trips to UK, US & over 90 nations, govt says

Bharat Biotech is believed to have assured Government of India that it will ‘quickly’ reply to WHO about ‘deficiencies found in its manufacturing’ during an inspection last month.

DCGI gives emergency use approval to Biological E’s Corbevax vaccine for kids aged 12-18

It is the second Covid vaccine to get approval for use in children in India after Bharat Biotech's Covaxin.

ICMR received Rs 171.74 cr in royalty from sale of Covaxin till 31 Jan, govt tells Rajya Sabha

ICMR and Bharat Biotech developed Covaxin together, and MoS Health Bharati Pawar says in written reply that the research body spent Rs 35 crore on its development.

Bharat Biotech gets DCGI’s nod to conduct ​clinical trials of intranasal Covid vaccine BBV154

The dosage form of the vaccine is liquid, containing 0.5ml/per dose for the intranasal route of administration. The trials will take place at nine different sites of the country.

Study shows Covaxin booster dose neutralises both Omicron, Delta variants: Bharat Biotech

Bharat Biotech said a study at Emory University demonstrated that people who got a Covaxin booster, 6 months after the two doses, witnessed neutralising of the two Covid variants.

Covaxin booster increases antibody levels by 19-97 fold against Covid variants: Phase 2 results

Study, which is yet to be peer-reviewed, was published on preprint portal medRxiv Saturday. It was conducted by Bharat Biotech and ICMR, which co-developed the vaccine.

Covaxin demonstrates robust safety and immunogenicity in 2-18-year-old volunteers, study says

The data was submitted to the Central Drugs Standard Control Organisation during October 2021 and received emergency use nod for children aged 12-18 from DCGI recently.

Covaxin was 50% effective among health workers in 2nd wave, real-world study from AIIMS shows

Study published in Lancet Infectious Diseases journal assessed 2,714 hospital workers from AIIMS New Delhi, who were most exposed to Covid and were primarily offered Covaxin.

Good news for kids: Expert panel gives Covaxin emergency approval for 2-18-year-olds

The phase 2/3 clinical trials for Covaxin for children were completed last month. The SEC will now send its recommendations to DCGI.

SII, Bharat Biotech get nod to export 10 lakh Covid vaccine doses under ‘Vaccine Maitri’

Ten lakh doses of Covaxin would be sent to Iran and 10 lakh doses of Covishield will be exported each to Myanmar, Nepal & Bangladesh under the ‘Vaccine Maitri’ programme in October.

On Camera

YourTurn

Title scene of Taarak Mehta ka ooltah chashmah.

Dear Taarak Mehta, you were our peak comfort content for 14 years. Now it’s time to retire

Just like the Truman Show, all Taarak Mehta plots somehow feel the same for the past few years. It's fine to accept that ideas can go stale.
File photo of chief economic advisor V. Anantha Nageswaran | Photo: Twitter | @FinMinIndia

Stock market turmoil, crypto craze proof of human ‘fear, greed’ says chief economic advisor

Speaking at India Ideas Conclave, organised by think tank India Foundation in Bengaluru, V. Anantha Nageswaran, also said India was now in position to deliver domestically-driven growth'.

Defence

File photo of a defence personnel armed with a SiG 716 rifle near the Line of Control | Photo: Snehesh Alex Philip | ThePrint

India to ink ‘repeat order’ deal for 73,000 SiG 716 rifles from the US

In February 2019, 72,400 SiG 716 rifles of 7.62 x 51mm calibre were contracted from SIG Sauer Inc, USA, under government's 'Buy (Global) category', through fast track procedure.

Mandir or Masjid? New surveys not needed, just acceptance of truth & move towards reconciliation

That temples were destroyed and mosques built is undisputed history. The past can’t be changed, but we can’t deny the wrongs of the past either before we consider reconciliation.
×